Metastatic Cancers
12
5
6
3
Key Insights
Highlights
Success Rate
75% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 37/100
8.3%
1 terminated out of 12 trials
75.0%
-11.5% vs benchmark
0%
0 trials in Phase 3/4
100%
3 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (12)
Combination Therapy for Cancer Related Fatigue in Patients With Metastatic Cancers
A Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic Cancer
e-Motion : Promoting Emotion Regulation in Chronic Cancer
Personalized Oncogenomics (POG) Program of British Columbia
A Phase II Study of Adjuvant Immunotherapy Targeting KRAS G12D, KRAS G12V, or TP53 R175H for Participants With Advanced Gastrointestinal Malignancies
Phase 2 Study Assessing Secured Access to Vemurafenib for Patients With Tumors Harboring BRAF Genomic Alterations
Assessing Systemic Treatment and ctDNA Monitoring Efficacy in Metastatic Cancer Patients Using K4Care Testing.
Study to Analyze Mutations in V600 BRAF Oncogen in Participants With Metastatic Melanoma
EXPRESS: EXcePtional RESponSe - Exceptional and Unexpected Response to Targeted Therapies
RADVAX: A Stratified Phase I Trial of Pembrolizumab With Hypofractionated Radiotherapy in Patients With Advanced and Metastatic Cancers
Vertebral Augmentation and Radiotherapy of Collapse Spinal Metastatic Cancer
Phase II/Pilot Study of 2nd Generation Anti-CEA Designer T Cells in Adenocarcinomas